{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:58:02Z","timestamp":1791406682138,"version":"4.3.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s10147-024-02563-7","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T12:15:29Z","timestamp":1717503329000},"page":"1302-1310","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Gustave Roussy Immune score as a prognostic biomarker in patients with platinum-refractory metastatic urothelial carcinoma treated with pembrolizumab: YUSHIMA study"],"prefix":"10.1007","volume":"29","author":[{"given":"Kenji","family":"Tanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7290-1826","authenticated-orcid":false,"given":"Shuichiro","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Maezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensaku","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Toide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanobu","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoji","family":"Takazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Numao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Ohtsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhisa","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"issue":"11","key":"2563_CR1","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ et al (2017) Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med 376(11):1015\u20131026. https:\/\/doi.org\/10.1056\/NEJMoa1613683","journal-title":"N Engl J Med"},{"issue":"6","key":"2563_CR2","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1093\/annonc\/mdz127","volume":"30","author":"Y Fradet","year":"2019","unstructured":"Fradet Y, Bellmunt J, Vaughn DJ et al (2019) Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol 30(6):970\u2013976. https:\/\/doi.org\/10.1093\/annonc\/mdz127","journal-title":"Ann Oncol"},{"key":"2563_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1398","author":"M Fujiwara","year":"2021","unstructured":"Fujiwara M, Yuasa T, Urasaki T et al (2021) Effectiveness and safety profile of pembrolizumab for metastatic urothelial cancer: a retrospective single-center analysis in Japan. Cancer Rep. https:\/\/doi.org\/10.1002\/cnr2.1398","journal-title":"Cancer Rep."},{"issue":"2","key":"2563_CR4","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/cas.14762","volume":"112","author":"T Kobayashi","year":"2021","unstructured":"Kobayashi T, Ito K, Kojima T et al (2021) Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab. Cancer Sci 112(2):760\u2013773. https:\/\/doi.org\/10.1111\/cas.14762","journal-title":"Cancer Sci"},{"issue":"12","key":"2563_CR5","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP et al (2021) Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 384(12):1125\u20131135. https:\/\/doi.org\/10.1056\/NEJMoa2035807","journal-title":"N Engl J Med"},{"issue":"10","key":"2563_CR6","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1200\/JCO.1999.17.10.3173","volume":"17","author":"DF Bajorin","year":"1999","unstructured":"Bajorin DF, Dodd PM, Mazumdar M et al (1999) Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17(10):3173\u20133181. https:\/\/doi.org\/10.1200\/JCO.1999.17.10.3173","journal-title":"J Clin Oncol"},{"issue":"11","key":"2563_CR7","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1200\/JCO.2009.25.4599","volume":"28","author":"J Bellmunt","year":"2010","unstructured":"Bellmunt J, Choueiri TK, Fougeray R et al (2010) Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 28(11):1850\u20131855. https:\/\/doi.org\/10.1200\/JCO.2009.25.4599","journal-title":"J Clin Oncol"},{"issue":"3","key":"2563_CR8","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s00262-020-02709-2","volume":"70","author":"T Kijima","year":"2021","unstructured":"Kijima T, Yamamoto H, Saito K et al (2021) Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab. Cancer Immunol Immunother 70(3):657\u2013665. https:\/\/doi.org\/10.1007\/s00262-020-02709-2","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"2563_CR9","doi-asserted-by":"publisher","first-page":"6124","DOI":"10.1002\/cam4.1820","volume":"7","author":"Y Feng","year":"2018","unstructured":"Feng Y, Xiong Y, Qiao T et al (2018) Lactate dehydrogenase A: a key player in carcinogenesis and potential target in cancer therapy. Cancer Med 7(12):6124\u20136136. https:\/\/doi.org\/10.1002\/cam4.1820","journal-title":"Cancer Med"},{"key":"2563_CR10","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ejca.2017.07.027","volume":"84","author":"F Bigot","year":"2017","unstructured":"Bigot F, Castanon E, Baldini C et al (2017) Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). Eur J Cancer 84:212\u2013218. https:\/\/doi.org\/10.1016\/j.ejca.2017.07.027","journal-title":"Eur J Cancer"},{"key":"2563_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1195499","author":"J Shangguan","year":"2023","unstructured":"Shangguan J, Huang X, Liu X et al (2023) Gustave Roussy immune score is a prognostic marker in patients with small cell lung cancer undergoing immunotherapy: a real-world retrospective study. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2023.1195499","journal-title":"Front Oncol"},{"issue":"3","key":"2563_CR12","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/oncolo\/oyac235","volume":"28","author":"LX Ma","year":"2023","unstructured":"Ma LX, Espin-Garcia O, Bach Y et al (2023) Comparison of four clinical prognostic scores in patients with advanced gastric and esophageal cancer. Oncologist 28(3):214\u2013219. https:\/\/doi.org\/10.1093\/oncolo\/oyac235","journal-title":"Oncologist"},{"issue":"2","key":"2563_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"2563_CR14","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5. Published: November 27. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute."},{"issue":"12","key":"2563_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051862","volume":"7","author":"J Budczies","year":"2012","unstructured":"Budczies J, Klauschen F, Sinn BV et al (2012) Cutoff finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization. PLoS ONE 7(12):e51862. https:\/\/doi.org\/10.1371\/journal.pone.0051862","journal-title":"PLoS ONE"},{"issue":"7","key":"2563_CR16","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/0959-8049(95)00664-8","volume":"32","author":"G Buccheri","year":"1996","unstructured":"Buccheri G, Ferrigno D, Tamburini M (1996) Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 32(7):1135\u20131141. https:\/\/doi.org\/10.1016\/0959-8049(95)00664-8","journal-title":"Eur J Cancer"},{"issue":"3","key":"2563_CR17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48(3):452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"issue":"3191","key":"2563_CR18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1126\/science.123.3191.309","volume":"123","author":"O Warburg","year":"1956","unstructured":"Warburg O (1956) On the origin of cancer cells. Science (1979) 123(3191):309\u2013314. https:\/\/doi.org\/10.1126\/science.123.3191.309","journal-title":"Science (1979)"},{"issue":"21","key":"2563_CR19","first-page":"6178","volume":"60","author":"BC Lewis","year":"2000","unstructured":"Lewis BC, Prescott JE, Campbell SE et al (2000) Tumor induction by the c-Myc target genes rcl and lactate dehydrogenase A. Cancer Res 60(21):6178\u20136183","journal-title":"Cancer Res"},{"issue":"1","key":"2563_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1475-2891-9-69","volume":"9","author":"D Gupta","year":"2010","unstructured":"Gupta D, Lis CG (2010) Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J 9(1):69. https:\/\/doi.org\/10.1186\/1475-2891-9-69","journal-title":"Nutr J"},{"issue":"1","key":"2563_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3233\/BLC-200354","volume":"7","author":"H Suzuki","year":"2021","unstructured":"Suzuki H, Ito M, Takemura K et al (2021) The Controlling Nutritional Status (CONUT) score is a prognostic biomarker in advanced urothelial carcinoma patients treated with first-line platinum-based chemotherapy. Bladder Cancer 7(1):13\u201321. https:\/\/doi.org\/10.3233\/BLC-200354","journal-title":"Bladder Cancer"},{"issue":"23","key":"2563_CR22","doi-asserted-by":"publisher","first-page":"5841","DOI":"10.1158\/1078-0432.CCR-18-0415","volume":"24","author":"DC Turner","year":"2018","unstructured":"Turner DC, Kondic AG, Anderson KM et al (2018) Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance. Clin Cancer Res 24(23):5841\u20135849. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0415","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2563_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2022.100848","volume":"46","author":"JH Park","year":"2022","unstructured":"Park JH, Park I, Kim IH et al (2022) Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure. Curr Probl Cancer 46(3):100848. https:\/\/doi.org\/10.1016\/j.currproblcancer.2022.100848","journal-title":"Curr Probl Cancer"},{"issue":"12","key":"2563_CR24","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1159\/000508923","volume":"98","author":"T Etani","year":"2020","unstructured":"Etani T, Naiki T, Sugiyama Y et al (2020) Low geriatric nutritional risk index as a poor prognostic marker for second-line pembrolizumab treatment in patients with metastatic urothelial carcinoma: a retrospective multicenter analysis. Oncology 98(12):876\u2013883. https:\/\/doi.org\/10.1159\/000508923","journal-title":"Oncology"},{"issue":"1","key":"2563_CR25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1179\/1607845414Y.0000000161","volume":"20","author":"BL Gaspar","year":"2015","unstructured":"Gaspar BL, Sharma P, Das R (2015) Anemia in malignancies: pathogenetic and diagnostic considerations. Hematology 20(1):18\u201325. https:\/\/doi.org\/10.1179\/1607845414Y.0000000161","journal-title":"Hematology"},{"issue":"10","key":"2563_CR26","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s41591-018-0205-5","volume":"24","author":"L Zhao","year":"2018","unstructured":"Zhao L, He R, Long H et al (2018) Late-stage tumors induce anemia and immunosuppressive extramedullary erythroid progenitor cells. Nat Med 24(10):1536\u20131544. https:\/\/doi.org\/10.1038\/s41591-018-0205-5","journal-title":"Nat Med"},{"issue":"11","key":"2563_CR27","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","volume":"25","author":"T Powles","year":"2019","unstructured":"Powles T, Kockx M, Rodriguez-Vida A et al (2019) Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med 25(11):1706\u20131714. https:\/\/doi.org\/10.1038\/s41591-019-0628-7","journal-title":"Nat Med"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02563-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-024-02563-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02563-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T01:03:10Z","timestamp":1724806990000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-024-02563-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,4]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["2563"],"URL":"https:\/\/doi.org\/10.1007\/s10147-024-02563-7","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,4]]},"assertion":[{"value":"26 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}